Toxic Injury

July 13, 2009

W. Va. Soldiers sue KBR for Chemical Exposure in Iraq

Russell Powell wondered for years after he returned from Iraq why he couldn’t run even short distances without wheezing.

Following his yearlong tour of duty that ended in 2004, he coached his son’s Little League team, but had to stop because it exhausted him.

The 34-year-old, who was able to run two miles in 9:44 before he went to Iraq in 2003, said now he is lucky to finish in 20 minutes.

He was discharged from the West Virginia Army National Guard for medical reasons at the end of 2008 because he was unable to meet physical requirements. Since he started his new job as a corrections officer for a West Virginia prison earlier this year, he’s had to use several sick days and vacation days to visit doctors.

July 11, 2009

Texas Firm Agrees to Clean up Mercury Spills to Settle Lawsuit

by Dr. Shezad Malik

Two years after several environmental groups sued, a Houston energy company has agreed to clean up mercury contamination around its natural gas wells in the Monroe area.

EnerVest Operating LLC will decontaminate land in Ouachita, Union and Morehouse parishes and replace about 400 leaky mercury meters the company uses to gauge well and pipeline pressure, according to a settlement approved last week by the U.S. District Court for the Western District of Louisiana.

The deal comes more than two years after EnerVest was sued for allowing mercury to seep into the land surrounding its wells in northeast Louisiana. The company failed to properly dispose of mercury and clean up spills from meters, according to the lawsuit filed by the Louisiana Audubon Council, the Sierra Club, the Gulf Restoration Network and the Louisiana Environmental Action Network. Nor did EnerVest upgrade its meters to more environmentally friendly models that have become “the industry standard,” the groups said.

July 10, 2009

Zicam Lawsuit and the FDA

by Dr. Shezad Malik

Has a Zicam nasal cold remedy robbed you of your sense of smell, and possibly the ability to taste? If so you have probably been stricken with a condition called anosmia – loss of sense of smell, sometimes accompanied by loss of sense of taste – related to the presence of zinc gluconate in Zicam intranasal cold remedies. Like thousands of other people who have used Zicam nasal gel or swabs, you probably had no idea that these products could be so dangerous.

Matrixx Initiatives, Inc. has had to remove several varieties of Zicam nasal cold remedies from the market because of their association with anosmia. The lawyers at our firm are currently representing scores of people in personal injury lawsuits who lost their ability to smell, and in some cases taste, after using a Zicam nasal gel or swab to treat or prevent a cold.

July 10, 2009

Midlothian Texas Residents to be Studied for Industrial Pollution

by Dr. Shezad Malik

Federal and state officials plan to interview about 100 Midlothian residents next week as part of an environmental study to see whether a link exists between industrial pollution and human and animal health problems, including birth defects.

Midlothian, southeast of Fort Worth, has 10 cement kilns, one of the largest concentrations in the country and a major source of industrial pollution in North Texas, according to environmental groups. Residents also worry about emissions from a steel plant in this community of about 15,000.

July 6, 2009

Zicam Lawsuit Filed

by Dr. Shezad Malik

Side effects of Zicam Nasal Gel and Nasal Swabs, marketed as an over-the-counter cold remedy, have been associated with the loss of sense of smell and taste, which can be an extremely devastating injury. In June 2009, the FDA required that three Zicam Cold Remedy products be pulled from the market due to reports of more than 130 users losing their sense of smell.

STATUS OF ZICAM LAWSUITS: Hundreds of Zicam lawsuits have been filed on behalf of individuals who lost their sense of taste or smell, and lawyers are continuing to review potential claims.

July 2, 2009

Roche Pulls Accutane Off Market After Jury Verdicts

by Dr. Shezad Malik

Roche Holding AG, the world’s biggest maker of cancer drugs, is pulling its Accutane acne medicine from the U.S. market after juries awarded at least $33 million in damages to users who blamed the drug for bowel disease.

Roche notified the U.S. Food and Drug Administration today that it was withdrawing Accutane after a “reevaluation” of its product lines showed it faced serious challenges from generic competitors, company officials said in a statement.

“In addition, Roche has been faced with high costs from personal-injury lawsuits that the company continues to defend vigorously,” according to the statement.

About 13 million people have taken Accutane since it went on the market in 1982. The medication was Roche’s second-biggest selling drug before the patent expired in 2002 and rivals started selling generic versions. Roche’s prescription market share of the drug is now below 5 percent, the company said.

July 1, 2009

Texas Asbestos Lung Mesothelioma Lawsuits

by Dr. Shezad Malik

In Texas, Asbestos been used in the petroleum industry in everything from pipe insulation to gaskets to the clothes workers wore. Asbestos causes cancer when breathed into the lungs, often in the form of Mesothelioma.

The fire benefits of asbestos were such that their use in Texas did not stop with the petroleum industry. The substance was used in building materials for homes, schools and buildings.

The state of Texas is in the top 10 when it comes to asbestos claims. At last count, it was placed seventh among all the states for the highest number of asbestos lawsuits filed and that number is expected to rise dramatically as the disease progresses.

July 1, 2009

FDA: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)

by Dr. Shezad Malik

FDA has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. The same changes to the prescribing information and Medication Guide for patients will also be required for bupropion products (Wellbutrin and generics)that are indicated for the treatment of depression and seasonal affective disorder.

June 30, 2009

Yaz Class Action Law Suits in Progress

by Dr. Shezad Malik

The Yaz® birth control pill has been on the market since 2006. Yaz is taken orally once daily to prevent pregnancy.

Yaz differs from other birth control methods because it contains a progestin hormone called drospirenone, which can increase potassium levels in the bloodstream.

Yaz has been linked with serious adverse heart problems. In a letter sent to the manufacturer of Yaz, the Food and Drug Administration warns of blood clots, heart attack, stroke, and gall bladder disease in Yaz users.

The FDA says, “Yaz has additional risks because it contains the progestin, drospirenone which can lead to hyperkalemia in high risk patients, which may result in potentially serious heart and health problems. Women taking Yaz must be concerned about the drug interactions that could increase potassium, in addition to the drug interactions common to all combination oral contraceptives.”

June 30, 2009

MRI Gadolinium Induced Kidney Failure

by Dr. Shezad Malik

Ever since the issue of MRI health risks began circulating, Gadolinium kidney failure has been debated—especially with its link to nephrogenic systemic fibrosis (NSF) and increased risk for MRI and kidney failure when used in association with MRI for persons with compromised kidneys.

However, a new study casts a certain amount of doubt. The study: High-Dose Gadodiamide for Catheter Angiography and CT in Patients With Varying Degrees of Renal Insufficiency: Prevalence of Subsequent Nephrogenic Systemic Fibrosis and Decline in Renal Function, was recently undertaken at the Mayo Clinic in Jacksonville, Florida.

The results of the study were published in the American Journal of Roentgenology.

“The purpose of our study was to evaluate the prevalence of nephrogenic systemic fibrosis and nephrotoxicity among patients with differing degrees of renal dysfunction who are exposed to high doses of gadodiamide,” said Mellena D. Bridges, MD, lead author of the study.